{
    "nctId": "NCT02939274",
    "briefTitle": "An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne\u00ae) for the Treatment of Cutaneous Metastases of Breast Cancer",
    "officialTitle": "N/A",
    "overallStatus": "UNKNOWN",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 15,
    "primaryOutcomeMeasure": "Objective Response Rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed Stage IIIb or IV breast cancer with cutaneous metastases.\n\nExclusion Criteria:\n\n* Participants receiving any medications or substances that are known to cause photosensitivity (e.g. tetracyclines, sulfonamides, phenothiazines, sulfonylurea hypoglycemic agents, thiazide diuretics, griseofulvin, fluoroquinolones, St. Johns' wort, amiodarone) are ineligible.\n* Participants who have received prior systemic therapy (chemotherapy or targeted therapy) within 7 days of Study Day 1 or those who have not recovered from clinically significant adverse events due to agents administered more than 7 days earlier. (continuation of the same regimen of HER-2 antibody targeted therapy agents, hormonal therapy and treatment with bisphosphonates or denosumab are permitted)\n* Participants who are receiving any other investigational agents during the proposed treatment cycle.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}